The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The 1990s might be viewed as a golden age for the therapy of metastatic breast cancer with the introduction of new cytotoxic drugs and regimens to improve quality of life and prolong survival. The taxanes and anthracyclines have emerged as the most active agents, and investigation of these drug classes in combination has been eagerly pursued. Increased understanding of the biology of breast cancer...
The management of metastatic breast cancer has evolved considerably in the last 5–6 years and a variety of treatments have been shown to impact on the natural history of this disease over this period, with demonstration of survival prolongation justifiably generating considerable excitement. However, the question may be asked whether the success and clinical utility of novel therapies should be defined...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.